Biotest is a specialist supplier of plasma proteins and biotherapeutic drugs used to treat diseases of the immune system or the haematopoietic system. The value chain of the medium-sized company, which was founded in 1946 as a family business, ranges from pre-clinical and clinical development to worldwide marketing. Biotest specialises primarily in the fields of clinical immunology, haematology as well as intensive care and emergency medicine. As the world market leader in hyperimmunoglobulins and the only manufacturer of IgM-enriched immunoglobulins, Biotest sees itself as an expert for innovative products for the prevention and therapy of life-threatening and rare infections. In addition, Biotest supports doctors and patients with coagulation factors that are also produced on the basis of human blood plasma. Among other things, the company has state-of-the-art plasmatic factor VIII and factor IX concentrates for the treatment of the congenital coagulation disorders haemophilia A and haemophilia B. Since 2019, the product portfolio also includes a first recombinant FVIII preparation from a human cell line. Biotest currently employs more than 2,000 people worldwide, the majority of whom are based at the company's headquarters in Dreieich near Frankfurt. The internationally active specialist supplier has subsidiaries in eight countries and sells its products in more than 80 countries. The plasma used is mainly obtained in the company's 22 plasma collection centres in Europe and meets the strictest official safety and quality requirements. Biotest manufactures all products exclusively in Germany. Privacy Statement and Imprint: https://www.biotest.com/de/en/service_navigation/privacy_statement/privacy-statement-imprint.cfm